Figure 7 from Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine

Figure 7 from Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine

<p>siRictor-NPs treatment synergizes with chemotherapy to diminish tumor cell survival and tumor growth in TNBC. <b>A</b> and <b>B,</b> HCC70 cells were treated with 100 nmol/L si-NPs ± paclitaxel in increasing doses. Cell viability was measured by CellTiter-Glo 2 days...

Full description

Saved in:
Bibliographic Details
Main Author: Shrusti S. Patel (20902043) (author)
Other Authors: Rebecca S. Cook (20902046) (author), Justin H. Lo (20902049) (author), Fiona K. Cherry (20902052) (author), Ella N. Hoogenboezem (20902055) (author), Fang Yu (20902058) (author), Nora Francini (20902061) (author), Nina T. Cassidy (20902064) (author), Joshua T. McCune (20902067) (author), Eva F. Gbur (20902070) (author), Lisa Messier (20902073) (author), Thomas A. Dean (20902076) (author), Kalin L. Wilson (20902079) (author), Dana M. Brantley-Sieders (20902082) (author), Craig L. Duvall (20902085) (author)
Published: 2025
Subjects:
Cancer
Therapeutic Research and Development
Biological Agents & Therapies
Breast Cancer
Nanoparticle Agents
Protein Kinase & Phosphatase Drug Targets
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items